Welcome to our dedicated page for Cencora SEC filings (Ticker: COR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cencora, Inc. filings document material events for a NYSE-listed pharmaceutical distribution and healthcare solutions company. Recent 8-K disclosures furnish quarterly operating results, Regulation FD information, executive officer transition details, annual meeting voting results and entries into material definitive agreements.
The company’s regulatory record also covers capital-structure matters, including common stock and listed senior notes, registered public debt offerings and the terms of multiple senior note maturities. Governance filings describe director elections and other shareholder voting matters, while material-event reports connect financing activity and completed acquisitions to the company’s operating and financial disclosures.
Cencora, Inc. (COR) director Lon R. Greenberg reported selling 1,280 shares of common stock on September 16, 2026 at $321.30 per share, for proceeds of about $411,264. After this open-market sale, he directly holds 17,128 shares of Cencora common stock. No Rule 10b5-1 trading plan is reported.
Cencora, Inc. (COR) director Lon R. Greenberg filed a Rule 144 notice indicating an intent to sell shares of Cencora common stock through Merrill Lynch. The notice covers shares received as director compensation, including 843 shares dated January 16, 2026 and 437 shares dated January 16, 2025.
Cencora, Inc. (COR) is the issuer for a planned Rule 144 sale of its common stock by former officer Silvana Battaglia. A brokerage account at Fidelity Brokerage Services LLC has filed to sell 1,324 shares of Cencora common stock, with a reported market value of $430,300.00 and 190,827,165 shares of common stock outstanding as of September 11, 2026. The notice also lists recent equity compensation events for Battaglia and discloses that 6,593 shares of Cencora common stock were sold on September 1, 2026 for $2,175,690.00.
Cencora, Inc. (COR) is the issuer in a notice where former officer James F. Cleary Jr., through Fidelity Brokerage Services LLC, plans to sell 10,000 shares of Cencora common stock under Rule 144. The filing lists Cencora common stock as traded on the NYSE.
The notice states an aggregate market value for the planned sale of $3,351,656.01 and reports that there were 190,827,165 shares outstanding as of September 4, 2026; this is a baseline figure, not the amount being sold. It also discloses that Cleary sold 20,000 shares during the prior three months for $6,333,096.30.
Cencora, Inc. (COR) reported that SVP & Chief Accounting Officer Lazarus Krikorian sold 985 shares of common stock on September 1, 2026 in an open market or private transaction at $325.97 per share. After this sale, he held 16,169 shares directly. The sale was effected under a Rule 10b5-1 trading plan adopted on June 3, 2026.
Cencora, Inc. (COR) is the issuer for a planned resale notice filed on behalf of former officer Silvana Battaglia under Rule 144. The notice covers up to 6,593 shares of common stock, with a stated aggregate market value of $2,175,690.00, to be sold through Fidelity Brokerage Services LLC on or after September 1, 2026. The shares relate to multiple restricted stock vesting events categorized as compensation.
Cencora, Inc. (COR) reported that Executive Vice President Elizabeth S. Campbell sold 11,300.471 shares of common stock on 2026-08-24 in an open market or private transaction. The weighted average sale price was $324.116 per share, based on multiple trades between $324.06 and $324.37. After this transaction, Campbell directly holds 19,455.085 shares of Cencora common stock. The Rule 10b5-1 checkbox was not marked as being pursuant to a trading plan.
Cencora, Inc. (COR) received a notice under Rule 144 that Elizabeth S. Campbell, an officer, may sell up to 11,301 shares of Cencora common stock through Fidelity Brokerage Services LLC on or after 08/24/2026 on the NYSE. These shares were acquired via employee stock purchase plan purchases and restricted stock vesting between 12/29/2023 and 03/11/2026. Cencora had 190,827,165 shares of common stock outstanding in this notice, and the shares covered have an indicated aggregate market value of $3,662,662.53.
Cencora, Inc. reported that director Lorence H. Kim, M.D., resigned from its Board of Directors effective immediately on August 13, 2026, following the conclusion of the Board’s quarterly meeting.
The company states that Dr. Kim’s decision is connected to his appointment as Chief Financial Officer of Commonwealth Fusion Systems, Inc. and his need to devote additional time to those professional responsibilities. Dr. Kim advised that his resignation is not due to any disagreement regarding Cencora’s operations, policies, or practices. The company expressed appreciation for his dedicated service.
Cencora, Inc. reports that beginning July 1, 2026, certain Walgreens volume that had been serviced separately from the existing prime vendor agreement began moving outside Cencora. The company states that the prime vendor agreement, which it describes as constituting the vast majority of its Walgreens business, remains unchanged.
Cencora also reaffirms its previously issued fiscal 2026 adjusted diluted EPS guidance in the range of $17.75 to $17.95. The company includes cautionary language that these are forward-looking statements based on current expectations and subject to risks and uncertainties described in its periodic reports.